Atorvastatin affects TLR4 clustering via lipid raft modulation

Area of Science:

• Immunology
• Cell Biology
• Pharmacology

Background:

• Statins, HMG-CoA reductase inhibitors, are widely used for hypercholesterolemia.
• Statins exhibit anti-inflammatory effects beyond lipid-lowering.
• Atorvastatin was previously shown to inhibit NF-kappaB activation in the LPS-TLR4 pathway.

Purpose of the Study:

• To investigate the anti-inflammatory mechanism of atorvastatin.
• To elucidate the role of Toll-like receptor 4 (TLR4) in atorvastatin's anti-inflammatory action.
• To determine if atorvastatin affects TLR4 signaling through receptor-ligand binding or other pathways.

Main Methods:

• Utilized murine pro-B cell lines transfected with TLR4.
• Stimulated cells with lipopolysaccharide (LPS) and co-treated with atorvastatin and mevalonate.
• Investigated TLR4 recruitment into lipid rafts and its effect on NF-kappaB activation.
• Blocked TLR4 to assess the receptor-ligand binding mechanism.

Main Results:

• Atorvastatin inhibits NF-kappaB activation in LPS-stimulated cells.
• Mevalonate co-treatment rescued NF-kappaB activation, indicating atorvastatin's effect is not directly on TLR4-ligand binding.
• Atorvastatin impairs TLR4 recruitment into lipid rafts, affecting downstream signaling.
• Mevalonate restored lipid raft function and TLR4 clustering.

Conclusions:

• Atorvastatin exerts anti-inflammatory effects through lipid raft modification.
• This mechanism involves disrupting TLR4 recruitment to lipid rafts.
• The findings provide novel insights into the pleiotropic effects of atorvastatin and potential applications for other signaling pathways utilizing lipid rafts.